Works by Mansoor Raza Mirza
Results: 23
Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2011, v. 103, n. 17, p. 1338, doi. 10.1093/jnci/djr282
- By:
- Publication type:
- Article
Patient care and access to clinical trials in gynaecological oncology: global implications of the early phase of the COVID-19 pandemic.
- Published in:
- Archives of Gynecology & Obstetrics, 2024, v. 310, n. 1, p. 577, doi. 10.1007/s00404-024-07511-4
- By:
- Publication type:
- Article
Patient-reported Outcomes in Patients With Primary Advanced or Recurrent Endometrial Cancer Who Received Dostarlimab Plus Carboplatin-Paclitaxel vs Carboplatin-Paclitaxel in the ENGOT-EN6/GOG3031/RUBY Trial.
- Published in:
- Journal of Oncology Navigation & Survivorship, 2023, v. 14, n. 11, p. 361
- By:
- Publication type:
- Article
Cancer of the corpus uteri: 2021 update.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Cancer of the corpus uteri.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Cancer of the corpus uteri.
- Published in:
- International Journal of Gynecology & Obstetrics, 2015, v. 131, p. S96, doi. 10.1016/j.ijgo.2015.06.005
- By:
- Publication type:
- Article
Cancer of the corpus uteri.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Cancer of the corpus uteri
- Published in:
- International Journal of Gynecology & Obstetrics, 2012, v. 119, n. s2, p. S110, doi. 10.1016/S0020-7292(12)60024-1
- By:
- Publication type:
- Article
A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
- Published in:
- BMC Cancer, 2014, v. 14, n. 1, p. 1, doi. 10.1186/1471-2407-14-937
- By:
- Publication type:
- Article
ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.
- Published in:
- Virchows Archiv: European Journal of Pathology, 2021, v. 478, n. 2, p. 153, doi. 10.1007/s00428-020-03007-z
- By:
- Publication type:
- Article
Implementing MyChoice® CDx HRD testing for the Nordics: lessons from 2021 to 2023.
- Published in:
- Acta Oncologica, 2024, v. 63, n. 1, p. 70, doi. 10.2340/1651-226X.2024.34139
- By:
- Publication type:
- Article
SystematiC nurse-led cONsultations based oN Electronic patient-reported outcome among women with ovarian- or endometrial Cancer during chemoTherapy – protocol for the CONNECT study.
- Published in:
- 2022
- By:
- Publication type:
- Letter
Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer.
- Published in:
- PLoS ONE, 2017, v. 12, n. 3, p. 1, doi. 10.1371/journal.pone.0174300
- By:
- Publication type:
- Article
Advances in the Management of Recurrent Cervical Cancer: State of the Art and Future Perspectives.
- Published in:
- Current Oncology Reports, 2023, v. 25, n. 11, p. 1307, doi. 10.1007/s11912-023-01463-9
- By:
- Publication type:
- Article
A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Patient perspectives and experiences of the rapid implementation of digital consultations during COVID-19 — a qualitative study among women with gynecological cancer.
- Published in:
- Supportive Care in Cancer, 2022, v. 30, n. 3, p. 2545, doi. 10.1007/s00520-021-06651-6
- By:
- Publication type:
- Article
Highlights in Ovarian Cancer From the 2021 American Society of Clinical Oncology Annual Meeting: A Review of Selected Presentations From the 2021 ASCO Annual Meeting.
- Published in:
- Clinical Advances in Hematology & Oncology, 2021, v. 19, p. 1
- By:
- Publication type:
- Article
A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Major clinical research advances in gynecologic cancer in 2019.
- Published in:
- Journal of Gynecologic Oncology, 2020, v. 31, n. 3, p. 1, doi. 10.3802/jgo.2020.31.e48
- By:
- Publication type:
- Article
Major clinical research advances in gynecologic cancer in 2018.
- Published in:
- Journal of Gynecologic Oncology, 2019, v. 30, n. 2, p. 1, doi. 10.3802/jgo.2019.30.e18
- By:
- Publication type:
- Article
Major clinical research advances in gynecologic cancer in 2017.
- Published in:
- Journal of Gynecologic Oncology, 2018, v. 29, n. 2, p. 1, doi. 10.3802/jgo.2018.29.e31
- By:
- Publication type:
- Article
Shall we settle for low-level evidence?
- Published in:
- Journal of Gynecologic Oncology, 2014, v. 25, n. 3, p. 162, doi. 10.3802/jgo.2014.25.3.162
- By:
- Publication type:
- Article
A multi-method approach to selecting PRO-CTCAE symptoms for patient-reported outcome in women with endometrial or ovarian cancer undergoing chemotherapy.
- Published in:
- Journal of Patient-Reported Outcomes, 2023, v. 7, n. 1, p. 1, doi. 10.1186/s41687-023-00611-w
- By:
- Publication type:
- Article